Persistence, adverse events, and relapse in patients with relapsing remitting multiple sclerosis and initiated on IFN Beta-1a or dimethyl fumarate

Authors
Category Primary study
JournalMultiple Sclerosis
Year 2017
This article has no abstract
Epistemonikos ID: 3a21227fb66ed76e5e3f600166201e2459763246
First added on: Feb 08, 2025